Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting
enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.